Wuxi Biologics suspended buying and selling in Hong Kong on Tuesday following a report droop in its share worth, after Washington added the Chinese language pharmaceutical large to a listing that might prohibit its US operations.
The Division of Commerce on Monday mentioned the corporate was amongst 33 Chinese language entities added to its unverified listing, which can pressure it to acquire further licences to do enterprise with American companies.
Wuxi Biologics, which produces vaccines and medicines on contract for pharmaceutical companies, mentioned the transfer would have “no influence” on its enterprise and that it was “in compliance with all